Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Na ïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis

ConclusionsThis analysis on Italian administrative data provided results about prescription patterns of ibrutinib FL and SLL new users with CLL, focusing on discontinuation, treatment change and healthcare costs over 2-year follow-up, and contributed to improve the knowledge on this hard-to-treat disease.

http://link.springer.com/10.1007/s40261-021-01044-3

Source: Clinical Drug Investigation - May 25, 2021 Category: Drugs & Pharmacology Source Type: research